Dashwood, who is also head of LPI's Cancer Chemoprotection Program, will be presenting some of this research in a talk titled "Metabolism as a key to HDAC inhibition by dietary constituents," at the American Society for Biochemistry and Molecular Biology's annual meeting. The talk will take place in Anaheim Convention Center Ballroom E on Wednesday, April 28 at 1:30 pm PST.

OSU scientists recently received an $8.5 million grant from the National Cancer Institute to explore these issues, making the LPI program one of the leaders in the nation on diet, epigenetics, and cancer prevention. The positive findings of laboratory research are already being converted to placebo-controlled human intervention trials on such health concerns as colon and prostate cancer, which are among the most common cancers in the United States.

OSU scientists have published a number of studies on these topics in professional journals such as Cancer Research, Cancer Prevention Research, Carcinogenesis, and Seminars in Cancer Biology. Among the most recent findings is that naturally occurring organoselenium compounds in the diet might prevent the progress of human prostate and colon cancer through an HDAC inhibition mechanism."Some therapeutic drugs already used for cancer treatment in the clinical setting probably work, at least in part, because they are acting as HDAC inhibitors," Dashwood said. "And what's most intriguing is that HDAC inhibition may affect many degenerative health issues, not just cancer. Heart disease, stroke, bipolar disorder, and even aging may all have links to HDAC/histone alterations.

"In the future, a single HDAC inhibitor conceptually could have benefits for more than one degenerative disease problem."

Source: American Society for Biochemistry and Molecular Biology